
Atai Life Sciences (NASDAQ:ATAI), a biotech company leading the development of psychedelic compounds for mental health purposes, issued its financial report for the first quarter of the year, ended March 31, 2022.
“We made great progress in the first quarter on our mission to achieve clinically meaningful behavioral change in people living with mental health disorders – seeing strong momentum across our three strategic pillars. We dosed the first subject in our Phase 1 KUR-101 trial and launched our fourth drug discovery program, Invyxis,” CEO Florian Brand said, who also highlighted the initiation of a usability study by Psyber, a portfolio company developing brain-computer interface technology in patients receiving ketamine treatment.